

Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for January 2020

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Mint Pharmaceuticals Inc.	Mint-Cetirizine	Reactine	cetirizine HCl	20mg	Tablet	02491125
Apotex Inc.	Apo-Prucalopride	Resotran	prucalopride succinate	1mg	FC tablet	02491591
Apotex Inc.	Apo-Prucalopride	Resotran	prucalopride succinate	2mg	FC tablet	02491605
Natco Pharma (Canada) Inc.	Nat-Pregabalin	Lyrica	Pregabalin	225mg	Capsule	02494892
Teva Canada Limited	Teva-Everolimus	Afinitor	everolimus	2.5mg	Tablet	02463229

Teva Canada Limited	Teva-Everolimus	Afinitor	everolimus	5mg	Tablet	02463237
Teva Canada Limited	Teva-Everolimus	Afinitor	everolimus	10mg	Tablet	02463253
Teligent Canada Inc.	Clindamycin Phosphate Topical Solution USP	Dalacin T	Clindamycin	1% w/v	topical solution	02483769
Pharmascience Inc.	Pms-Anagrelide	Agrylin	anagrelide HCl monohydrate	0.5mg	capsule	02274949